Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05156788
What this trial is testing

Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Who this might be right for
Biliary Tract CancerPD-1 AntibodyGemox+1 more
Shanghai Zhongshan Hospital 40
Post-approval studies (Phase 4)UnknownNCT04040491
What this trial is testing

PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma

Who this might be right for
Peripheral T-cell Lymphoma
Mingzhi Zhang 100
Testing effectiveness (Phase 2)Looking for participantsNCT06925724
What this trial is testing

Ivonescimab in People With Endometrial and Cervical Cancers

Who this might be right for
Endometrial CancerCervical Cancer
Memorial Sloan Kettering Cancer Center 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT06015724
What this trial is testing

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

Who this might be right for
Pancreatic Ductal AdenocarcinomaRefractory Non-Small Cell Lung Cancer
Georgetown University 19
Testing effectiveness (Phase 2)Study completedNCT04435197
What this trial is testing

Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma
Ruijin Hospital 143
Early research (Phase 1)Active Not RecruitingNCT06082960
What this trial is testing

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

Who this might be right for
Solid Tumors
Gilead Sciences 45
Not applicableLooking for participantsNCT06323382
What this trial is testing

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Who this might be right for
Advanced Hepatocellular CarcinomaAnti-PD1/PDL1 AntibodyBevacizumab
Sun Yat-sen University 240
Early research (Phase 1)Study completedNCT05498480
What this trial is testing

Study of Relatlimab in Combination With Nivolumab in Chinese Participants

Who this might be right for
Advanced Solid Tumors
Bristol-Myers Squibb 6
Testing effectiveness (Phase 2)UnknownNCT03704246
What this trial is testing

Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Taizhou Hanzhong biomedical co. LTD 123
Large-scale testing (Phase 3)Active Not RecruitingNCT06304974
What this trial is testing

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)

Who this might be right for
Esophageal Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd. 497
Testing effectiveness (Phase 2)UnknownNCT04338282
What this trial is testing

Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma

Who this might be right for
Extranodal NK/T-cell Lymphoma, Nasal Type
Beijing Tongren Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT07070479
What this trial is testing

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Who this might be right for
Recurrent or Metastatic Nasopharyngeal Carcinoma
Ming-Yuan Chen 208
Not applicableActive Not RecruitingNCT07581769
What this trial is testing

Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC Downstaging

Who this might be right for
Hepatocellular Carcinoma (HCC)DownstagingLiver Resection+3 more
First Affiliated Hospital, Sun Yat-Sen University 500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06099951
What this trial is testing

Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy

Who this might be right for
Colorectal Cancer
Sun Yat-sen University 53
Testing effectiveness (Phase 2)Ended earlyNCT03777124
What this trial is testing

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Who this might be right for
NSCLC Stage IVKRAS Gene MutationPD-1 Antibody+1 more
Jiangsu HengRui Medicine Co., Ltd. 25
Testing effectiveness (Phase 2)Looking for participantsNCT07050186
What this trial is testing

Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma

Who this might be right for
Metastatic NUT CarcinomaUnresectable NUT Carcinoma
Northwestern University 15
Testing effectiveness (Phase 2)Study completedNCT05189093
What this trial is testing

Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma

Who this might be right for
Relapsed/Refractory Lymphoma
Hangzhou Hanx Biopharmaceuticals, Ltd. 48
Large-scale testing (Phase 3)Study completedNCT04702009
What this trial is testing

Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer

Who this might be right for
Advanced Lung CarcinomaNon-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 33
Testing effectiveness (Phase 2)Study completedNCT04693234
What this trial is testing

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

Who this might be right for
Cervical Cancer
BeiGene 178
Early research (Phase 1)Looking for participantsNCT05547321
What this trial is testing

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

Who this might be right for
Advanced Solid Tumor
Oncomatryx Biopharma S.L. 150
Next Page